Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
President-elect Joe Biden hit the ground running this morning with the announcement of his transition team’s COVID-19 advisory board.
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
Shares of Endo International are up more than 5% after the company announced positive earnings Thursday and also announced a new restructuring plan.
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion. Novo Nordisk and Emisphere have been partnered since 2007.
According to recent polls, less than half of Americans trust pharmaceutical companies. In fact, only 42% of respondents say they have any trust in pharma, with a paltry 6% having a great deal.
Special purpose acquisition companies (SPACs) are resurging as a virtually hassle-free alternative to initial public offerings (IPOs). They’ve been around for years, but are just now becoming a factor for biotech.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The current pandemic has caused a major decrease in big money investments into mergers and acquisitions. Could company collaborations be the skeleton key needed to drive life sciences?
The Healthcare Technology Report announced on Nov. 3 its list of the Top 25 Women Leaders in Biotechnology of 2020.